Is BPC-157 Legal? Where It Stands Right Now

BPC-157 is not an FDA-approved drug for any use. It also can't legally be made by a US compounding pharmacy right now, because it isn't on the FDA's 503A bulks list and isn't in Category 1 of the FDA's interim system. An FDA advisory committee recommended changing that in July 2026, but the FDA hasn't acted on the recommendation.

BPC-157 is a synthetic peptide made of 15 amino acids. It's been studied mostly in animals for tissue repair and gut healing. It has also been studied as a possible treatment for ulcerative colitis, which is the use the FDA's advisory committee considered. Human clinical evidence is limited, which is the main reason FDA staff have been cautious.

2023: The FDA placed BPC-157 in Category 2, its list of substances that raise significant safety risks in compounding. That effectively blocked pharmacies from compounding it.

April 2026: The FDA removed BPC-157 and 11 other peptides from Category 2 after their nominations were withdrawn. This was widely reported as a loosening, but removal from Category 2 doesn't by itself authorize compounding. BPC-157 went into a gray zone: no longer flagged, but not permitted either.

July 23, 2026: The FDA's Pharmacy Compounding Advisory Committee voted 8–6, with one abstention, to recommend adding BPC-157 to the 503A bulks list. FDA staff had recommended against it, citing limited evidence of effectiveness and the availability of approved treatments for ulcerative colitis. Our breakdown of the July vote covers the details.

October 14, 2026: The FDA sent an interim access policy for compounding certain peptides to the White House budget office for review. The text isn't public yet. If it takes effect, it could allow temporary compounding of some peptides while formal rulemaking continues.

Advisory committee votes are recommendations. To add BPC-157 to the bulks list, the FDA has to publish a proposed rule, take public comments, and then publish a final rule. The agency doesn't have to follow the committee's vote, and its own staff opposed this one. Industry observers expect formal rulemaking to take until mid-to-late 2027 at the earliest.

Many websites sell BPC-157 labeled "for research use only" or "not for human consumption." Those labels don't make products legal to sell for human use. The FDA has sent a series of warning letters to online peptide sellers in 2025 and 2026, judging what a product is for by the whole website, not the label. These products aren't made under drug manufacturing standards, so what's in the vial may not match the label.

BPC-157 isn't a federally controlled substance. The legal issue is that it's an unapproved drug, which governs how it can be sold and marketed.

BPC-157 is on the World Anti-Doping Agency's 2026 prohibited list, and it's banned for US military personnel. Both apply strict liability, meaning a positive test counts regardless of how the substance got there.

1. Identify the jurisdiction. A US FDA statement does not determine rules in another country.
2. Open the original document. Distinguish an agency action from a company's interpretation of it.
3. Check the stage. A proposal, an advisory discussion, a final rule, and an effective policy are different things.
4. Check scope and dates. Which substance, form, pathway, and conditions are covered?
5. Keep clinical evidence separate. A change in access does not show that something works.

If a provider describes a product as approved, ask for its approval record. If the claim is about compounding, ask which current rule allows it.

The next real change will come from the interim access policy clearing White House review, or from the FDA publishing a proposed rule on the July votes. We update this page and our FDA status tracker when either happens.